Penumbra Inc (PEN)

Currency in USD
240.10
-0.29(-0.12%)
Closed·
After Hours
240.10+0.16(+0.07%)
·
PEN Scorecard
Full Analysis
Net income is expected to grow this year
PEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
236.26241.09
52 wk Range
163.63310.00
Key Statistics
Prev. Close
240.1
Open
240.11
Day's Range
236.26-241.09
52 wk Range
163.63-310
Volume
551.77K
Average Volume (3m)
511.85K
1-Year Change
35.22%
Book Value / Share
33.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
310.88
Upside
+29.48%
Members' Sentiments
Bearish
Bullish
ProTips
14 analysts have revised their earnings downwards for the upcoming period

Penumbra Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Penumbra Inc Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Inc SWOT Analysis


Innovation Powerhouse
Penumbra's cutting-edge neurovascular and vascular technologies drive growth in an under-penetrated market, positioning it as a key industry playe
Financial Resilience
Strong Q3 2024 performance with revenue growth of 16.96%, yet conservative guidance maintains caution amid market uncertainties
Analyst Perspectives
Price targets range from $230 to $323, reflecting varied expectations for Penumbra's future performance in a competitive medical device landscape
Strategic Challenges
Penumbra navigates segment-specific issues and regulatory hurdles while leveraging its innovation pipeline to capture market share and drive expansion
Read full SWOT analysis

Penumbra Inc Earnings Call Summary for Q2/2025

  • Penumbra Inc. beats Q2 2025 estimates with EPS of $0.86 and revenue of $339.5M, up 13.4% YoY
  • Full-year revenue guidance raised to $1.355B-$1.370B, projecting 13-15% growth
  • U.S. sales grew 19.5%, while international sales declined 3.2%; gross margin at 66% with 70%+ target by 2026
  • CEO highlights market share gains in DVT and PE markets; company maintains strong financial health with no debt
  • Stock fell 1.31% despite positive earnings, closing at $230.17; company expects continued growth in thrombectomy market
Last Updated: 29/07/2025, 22:58
Read Full Transcript

Compare PEN to Peers and Sector

Metrics to compare
PEN
Peers
Sector
Relationship
P/E Ratio
63.0x−3.4x−0.5x
PEG Ratio
0.070.150.00
Price/Book
7.2x1.8x2.6x
Price / LTM Sales
7.3x2.4x3.3x
Upside (Analyst Target)
33.3%68.9%42.8%
Fair Value Upside
Unlock9.6%6.5%Unlock

Analyst Ratings

14 Buy
4 Hold
0 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 310.88
(+29.48% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
0.86 / 0.83
Revenue / Forecast
339.50M / 327.77M
EPS Revisions
Last 90 days

PEN Income Statement

People Also Watch

264.75
AVAV
-1.19%
45.130
SMR
+4.03%
867.12
AXON
+16.41%
153.93
CRCL
-6.61%
25.89
CNC
-1.22%

FAQ

What Stock Exchange Does Penumbra Inc Trade On?

Penumbra Inc is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Penumbra Inc?

The stock symbol for Penumbra Inc is "PEN."

What Is the Penumbra Inc Market Cap?

As of today, Penumbra Inc market cap is 9.30B.

What Is Penumbra Inc's Earnings Per Share (TTM)?

The Penumbra Inc EPS (TTM) is 3.83.

When Is the Next Penumbra Inc Earnings Date?

Penumbra Inc will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is PEN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Penumbra Inc Stock Split?

Penumbra Inc has split 0 times.

How Many Employees Does Penumbra Inc Have?

Penumbra Inc has 4500 employees.

What is the current trading status of Penumbra Inc (PEN)?

As of 06 Aug 2025, Penumbra Inc (PEN) is trading at a price of 240.10, with a previous close of 240.10. The stock has fluctuated within a day range of 236.26 to 241.09, while its 52-week range spans from 163.63 to 310.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.